Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Taps Novartis Oncology Firepower For Lenvima

This article was originally published in PharmAsia News

Executive Summary

Following the recent approval of Lenvima for kidney cancer in the US, Eisai has allied with major oncology player Novartis to help drive sales of the product in this market.

You may also be interested in...



New Indication For Lenvima In India Spawns Opportunities For Many?

Eisai’s lenvatinib is endorsed by an expert panel in India in combination with everolimus, for which multiple generic brands are available in addition to Novartis’ Afinitor. The Swiss multinational isn’t allying with Eisai in India at least for now.

Kidney Cancer Gets A Double Uplift From Latest CHMP Meeting

During its July 2016 meeting, the EU's top scientific advisory panel, the Committee for Medicinal Products for Human Use, recommended approval for two anticancers, cabozantinib and lenvatinib, that will likely shake up the advanced kidney cancer sector, and a new therapy for pancreatic cancer, liposomal and pegylated irinotecan.

Kyowa Kirin’s Parkinson’s Successor Shows Phase IIb Promise

Positive clinical results in Parkinson’s pave path forward for Japanese firm’s potential istradefylline successor.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel